Multiple inflammatory biomarker detection in a prospective cohort study: a cross-validation between well-established single-biomarker techniques and electrochemiluminescense-based multi-array platform by Bussel, B.C.T., van et al.
Multiple Inflammatory Biomarker Detection in a
Prospective Cohort Study: A Cross-Validation between
Well-Established Single-Biomarker Techniques and an
Electrochemiluminescense-Based Multi-Array Platform
Bas C. T. van Bussel1,2,3*, Isabel Ferreira1,4,5,6, Marjo P. H. van de Waarenburg1,3, Marleen M. J. van
Greevenbroek1,6, Carla J. H. van der Kallen1,6, Ronald M. A. Henry1,3,6, Edith J. M. Feskens3,7,
Coen D. A. Stehouwer1,2,3,6, Casper G. Schalkwijk1,3,6
1Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands, 2Nutrition and Toxicology Research Institute Maastricht (NUTRIM),
Maastricht University, Maastricht, The Netherlands, 3 Top Institute Food and Nutrition (TIFN), Wageningen, The Netherlands, 4Department of Clinical Epidemiology and
Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands, 5Care and Public Health Research Institute (CAPHRI),
Maastricht University, Maastricht, The Netherlands, 6Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands, 7Division of
Human Nutrition, Wageningen University, Wageningen, The Netherlands
Abstract
Background: In terms of time, effort and quality, multiplex technology is an attractive alternative for well-established single-
biomarker measurements in clinical studies. However, limited data comparing these methods are available.
Methods: We measured, in a large ongoing cohort study (n = 574), by means of both a 4-plex multi-array biomarker assay
developed by MesoScaleDiscovery (MSD) and single-biomarker techniques (ELISA or immunoturbidimetric assay), the
following biomarkers of low-grade inflammation: C-reactive protein (CRP), serum amyloid A (SAA), soluble intercellular
adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1). These measures were realigned by
weighted Deming regression and compared across a wide spectrum of subjects’ cardiovascular risk factors by ANOVA.
Results: Despite that both methods ranked individuals’ levels of biomarkers very similarly (Pearson’s r all$0.755) absolute
concentrations of all biomarkers differed significantly between methods. Equations retrieved by the Deming regression
enabled proper realignment of the data to overcome these differences, such that intra-class correlation coefficients were
then 0.996 (CRP), 0.711 (SAA), 0.895 (sICAM-1) and 0.858 (sVCAM-1). Additionally, individual biomarkers differed across
categories of glucose metabolism, weight, metabolic syndrome and smoking status to a similar extent by either method.
Conclusions: Multiple low-grade inflammatory biomarker data obtained by the 4-plex multi-array platform of MSD or by
well-established single-biomarker methods are comparable after proper realignment of differences in absolute
concentrations, and are equally associated with cardiovascular risk factors, regardless of such differences. Given its greater
efficiency, the MSD platform is a potential tool for the quantification of multiple biomarkers of low-grade inflammation in
large ongoing and future clinical studies.
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Introduction
Biomarker measurements representing low-grade inflammation
have gained increasing importance in the management and
understanding of cardiovascular disease (CVD) [1–8]. Low-grade
inflammation is accompanied by inflammatory cells that closely
interact with the arterial wall, thereby driving the development of
atherosclerosis and CVD [1,2]. Because the role of low-grade
inflammation in the pathophysiology of CVD is multi-faceted
[1,2], an extensive characterization by multiple biomarkers of low-
grade inflammation is desirable. In this line, large cohort studies
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are increasingly adopting such a multiple biomarker approach [8–
15].
Among a large variety of potential biomarkers [16], acute-phase
reactants such as C-reactive protein (CRP) and serum amyloid A
(SAA), and vascular adhesion molecules such as soluble intercel-
lular adhesion molecule-1 (sICAM-1) and soluble vascular cell
adhesion molecule-1 (sVCAM-1) reflect low-grade inflammation
when present in low concentrations [1,2], whereas high concen-
trations, such as CRP.10mg/l, more likely reflect acute
inflammation or infection [9,17,18]. These four biomarkers of
low-grade inflammation were studied because they play an
important role in the pathophysiology of CVD [1,2] and higher
concentrations have been associated with (incident) CVD [3–8].
Traditionally, well-established analytical methods have enabled
the analysis of single biomarkers of low-grade inflammation in one
run. However, obtaining multiple biomarkers based on many
single-biomarker measurements is very labor intensive, expensive
and requires (relatively) large sample volumes. These limitations
hamper an efficient multiple biomarker approach, particularly in
large observational cohort or clinical trial studies. An attractive
solution to these limitations is the simultaneous, and thus more
efficient, measurement of a set of low-grade inflammatory
biomarkers in one run. Such methods have recently become
available with the use of multi-array platforms, such as the
LuminexH and the MesoScaleDiscoveryH (MSD) platforms and
provide the tools necessary for efficient multiple biomarker
detection. However, it remains to be established to what extent
biomarker concentrations, as measured with these multi-array
platforms, are comparable to well-established single-biomarker
measurements. Although some cross-validation studies have been
performed, most have not focused on biomarkers of low-grade
inflammation [19–23] and the only study that did so pointed the
problem of different measured concentrations, which may lead to
bias in epidemiological associations [23].
Therefore, introducing a multi-array platform in the context of
an ongoing longitudinal cohort study poses some challenges
[24,25] and cross-validation between methods within such a
cohort is necessary before the ‘new’ method may replace the ‘old’
one. Specifically, one needs to determine whether substantial
differences in biomarker concentrations are introduced by the new
method, in which case realignment of the data by appropriate
mathematical transformations may be required for the investiga-
tion of within-subjects changes in absolute concentrations of
biomarkers over the course of time [26,27]. In addition, the data
obtained need also to be similarly associated with risk factors (RFs)
known to be associated with low-grade inflammation to ensure
that the multi-array platform measures what it intends to measure
(i.e. face validity).
In view of these considerations, we compared the performance
of a 4-plex multi-array electrochemiluminescense detection
platform of low-grade inflammatory biomarkers (CRP, SAA,
sICAM-1 and sVCAM-1) of MSD with that of well-established
single-biomarker measurements, in a large ongoing cohort study of
individuals with a wide spectrum of cardiovascular risk factors
(RFs) known to be associated with low-grade inflammation.
Materials and Methods
Ethics Statement
The study was approved by the Medical Ethical Committee of
the Maastricht University and all individuals gave written
informed consent.
Study Population and Design
The Cohort on Diabetes and Atherosclerosis Maastricht
(CODAM) is a prospective cohort study that was originally
designed to study the effects of obesity, glucose and lipid
metabolism, lifestyle and genetics on cardiovascular complications,
as described in detail elsewhere [28–33]. Briefly, individuals were
selected from a large population-based cohort and included if they
were of Caucasian ethnicity and older than 40 years, and met one
or more of the following criteria: a body mass index (BMI)
$25 kg/m2, a positive family history for type 2 diabetes mellitus, a
history of gestational diabetes, use of anti-hypertensive medication,
a postprandial glucose $6.0 mmol/l and/or glucosuria. In total,
574 individuals [mean age 59.667.0 years; 38.7% women] were
included and extensively characterized with regard to their
metabolic, cardiovascular and lifestyle risk profiles during 2 visits
to the University research unit (CODAM-1, baseline examination:
September 1999-July 2002). A first follow-up examination took
place among 495 individuals (14% drop-out rate, mainly due to
morbidity or mortality) approximately 7 years later (CODAM-2,
July 2006-November 2009).
At baseline (i.e. CODAM-1), biomarkers of low-grade inflam-
mation were assessed by single-biomarker techniques. At follow-up
(i.e. CODAM-2), the single-biomarker techniques were replaced
by the multi-array platform of MSD. To ensure comparability
between methods, biomarkers of low-grade inflammation were
also reassayed by the multi-array platform of MSD in all samples
from the baseline examination (i.e. CODAM-1); at the time of
these measurements, baseline samples had thus been stored for ,7
years. The present cross-validation study reports on individuals’
paired data on biomarkers during the baseline examination
(CODAM-1) and thus is a cross-sectional method comparison
study. Method comparison for each biomarker was conducted on
paired data, which were available for CPR in 566 individuals, for
SAA in 563 individuals, for sICAM-1 in 566 individuals and for
sVCAM-1 in 567 individuals and full paired data on all four
inflammatory biomarkers were available in 550 individuals.
The CODAM study population is characterized by a wide
spectrum of conditions known to be associated with low-grade
inflammation [28–33]. Specifically, 52.4% of the individuals had
normal glucose metabolism (NGM), 22.2% had impaired glucose
metabolism (IGM) and 25.4% had type 2 diabetes mellitus (DM2)
[28–33]. On the basis of measured BMI, the prevalence of normal
weight, overweight and obesity was 18.2, 50.9 and 30.9%,
respectively [32]. The metabolic syndrome, i.e. the clustering of
$3 out of 5 cardiovascular RFs reflecting central obesity,
dyslipidemia, elevated blood pressure and fasting plasma glucose,
was prevalent in 54.7% of the study population [30,31]. On the
basis of self-reports, 29.3% of the individuals were never-smokers,
50.5% were ex-smokers and 20.2% were current smokers [33].
The prevalence of CVD was 27.6% and based on self-reports of
myocardial infarction, coronary bypass surgery, stent placement or
balloon dilatation, transient ischemic attack or stroke, abnormal-
ities on a 12-lead electrocardiogram?(Minnesota codes 1.1 to 1.3,
4.1 to 4.3, 5.1 to 5.3 or 7.1) and(or) self-reported narrowing of
peripheral arteries, non-traumatic limb amputation or a measured
ankle-arm index ,0.9 [30,31]. Glycated hemoglobin [(mean 6
SD) 6.060.82%] was measured as previously described [28–33].
Estimated glomerular filtration rate (eGFR) [(mean 6 SD)
95.7619.0 mL/min/1.73 m2] was calculated on the basis of
individuals’ age, sex and serum creatinine levels according to the
short Modification of Diet in Renal Disease (MDRD) equation
[34].
Cross-Validation of Multi-Array Technology
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Biomarker Assessments
Individuals were asked to stop their lipid-lowering medication
14 days prior to the blood withdrawals and all other medication on
the day before. After an overnight fast (duration of at least 10
hours) blood was drawn from the anticubital vein and collected in
EDTA polypropylene tubes for plasma and in clot activator
containing polypropylene tubes for serum. EDTA tubes were
centrifuged at 3000 rpm for 15 min at 4uC, and plasma was
immediately divided into 1 ml aliquots and stored in 280uC
freezers until further analysis. Tubes with cloth activator were left
20 minutes before centrifugation at 3000 rpm for 15 min at 20uC,
and serum was immediately divided into 1 ml aliquots and stored
in 220uC freezers until analysis [28].
Biomarker detection by single-biomarker
techniques. CRP was measured in a single measurement in
serum with a high-sensitivity, immunoturbidimetric assay (detec-
tion range 100 ng/ml to 20000 ng/ml, i.e. factor 200) (Latex,
Roche Diagnostics Netherlands BV, Almere, The Netherlands,
www.roche.nl). This assay is based on the principle of particle-
enhanced immunological agglutination. Briefly, anti-CRP anti-
bodies coupled to latex micro-particles react with antigen present
in the sample to form antigen-antibody complexes. Then, these
micro-particles with antigen-antibody complexes agglutinate. This
changes the fluid turbidity of the sample, which is detected by
turbidimetry. sVCAM-1 was measured in EDTA plasma with a
high-sensitivity human Quantikine ELISA kit (detection range
6.25 ng/ml to 200 ng/ml, i.e. factor 32) (R&D Systems,
Minneapolis, MN, USA, www.rndsystems.com). sICAM-1 (detec-
tion range 0.625 ng/ml to 10 ng/ml, i.e. factor 16) and SAA
(detection range 9.4 ng/ml to 600 ng/ml, i.e. factor 64) were
measured in EDTA plasma by ELISA (Biosource, Invitrogen,
Carlsbad, CA, USA, www.invitrogen.com). All low-grade inflam-
matory biomarkers were measured at the Laboratory of
Toxicology, Genetics and Pathology of the National Institute for
Public Health and the Environment, Bilthoven, The Netherlands
[30]. The intra- and inter-assay coefficients of variation (CVs) for
these assays were, for CRP, 0.6% and 1.9%; for SAA, 6.1% and
17.5%; for sICAM-1, 5.6% and 6.6%; and for sVCAM-1, 3.1%
and 4.7%, respectively.
Biomarker detection by the 4-plex multi-array
electrochemiluminescense detection platform of
MesoScaleDiscovery. The 4-plex multi-array electrochemilu-
minescence platform of MesoScaleDiscovery (detection range
0.008 ng/ml to 1000 ng/ml, i.e. factor 125000) (MesoScaleDis-
covery, Gaithersburg, MD, USA, www.mesoscale.com) was used
to measure the four low-grade inflammatory biomarkers (CRP,
Table 1. Absolute biomarker concentrations in the total population and according to glucose metabolism, weight, metabolic
syndrome and smoking status as determined by the single-biomarker techniques or by the multi-array platform of
MesoScaleDiscovery.
CRP (mg/l) SAA (mg/l) sICAM-1 (mg/l) sVCAM-1 (mg/l)
Immunoturbidimetry Multi-array ELISA Multi-array ELISA Multi-array ELISA Multi-array
Total population (n = 550) 2.6 [1.4–4.5] 1.9 [0.9–3.8] 7.0 [4.0–13.8] 1.3 [0.8–2.2] 350691 219654 4766121 339675
Glucose metabolism statusa
NGM (n= 291) 2.2 [1.3–3.7] 1.6 [0.9–3.1] 6.2 [3.7–11.8] 1.2 [0.7–2.0] 338685 210650 4636121 331673
IGM (n = 122) 2.8 [1.5–4.8] 2.1 [1.0–3.9] 8.0 [4.5–14.9] 1.3 [0.9–2.6] 354690 220648 4676105 338668
DM2 (n = 137) 3.2 [1.9–5.7] 2.4 [1.3–5.3] 8.1 [4.7–15.5] 1.5 [1.0–2.6] 3736100 237663 5106127 356682
Weight statusb
Normal weight (n = 100) 1.4 [0.9–3.0] 1.0 [0.5–2.4] 5.3 [3.0–12.0] 1.0 [0.6–1.9] 326699 205650 4546130 323670
Overweight (n = 283) 2.2 [1.4–3.8] 1.6 [0.9–3.1] 6.4 [4.2–12.6] 1.2 [0.8–2.0] 341679 214647 4676114 334673
Obese (n = 167) 3.6 [2.3–6.0] 3.0 [1.6–5.4] 8.6 [5.2–15.8] 1.6 [1.0–2.7] 380698 238662 5056121 357676
Metabolic syndrome statusc
0–1 risk factor (n = 134) 1.5 [0.9–3.1] 1.0 [0.5–2.4] 5.6 [3.4–11.6] 1.1 [0.7–1.8] 317675 198642 4476106 322665
2 risk factors (n = 119) 2.4 [1.3–3.8] 1.8 [0.9–3.2] 6.5 [4.0–14.7] 1.3 [0.8–2.5] 334680 205641 4646117 324667
$3 risk factors d (n = 297) 3.0 [1.8–5.2] 2.4 [1.3–4.7] 7.7 [4.5–14.2] 1.4 [0.9–2.4] 372696 235658 4946126 352679
Smoking status
Never (n = 161) 2.1 [1.3–3.4] 1.5 [0.9–2.7] 6.1 [3.8–13.6] 1.3 [0.8–2.1] 331682 211649 4856125 337675
Ex-smoker (n = 278) 2.6 [1.4–4.6] 2.0 [0.9–3.9] 6.8 [4.2–12.6] 1.3 [0.8–2.0] 347688 217657 4816117 344673
Current (n = 111) 3.2 [1.5–5.5] 2.4 [1.0–5.3] 9.4 [4.5–15.6] 1.5 [0.9–2.7] 3856101 237650 4506122 327678
Data are means 6 SD or medians [interquartile range].
aNGM, normal glucose metabolism: defined as fasting plasma glucose ,6.1 mmol/l and 2-hour post-load plasma glucose ,7.8 mmol/l; IGM, impaired glucose
metabolism: includes impaired fasting plasma glucose (between 6.1 mmol/l and 7.0 mmol/l) and/or impaired glucose tolerance (2-hour post-load plasma glucose
between 7.8 and 11.1 mmol/l); DM2, diabetes mellitus type 2 (fasting plasma glucose $7.0 mmol/l and/or 2-hour post-load plasma glucose $11.1 mmol/l);
bCategorized on the basis of individuals’ body mass index (BMI) as: normal (if BMI 18.5–24.9 kg/m2); overweight (if BMI $25.0 and ,29.9 kg/m2), and obese (if BMI
$30 kg/m2);
cMetabolic syndrome status was defined according to the revised NCEP-ATPIII definition (American Heart Association/National Heart, Lung and Blood Institute);
dany 3 out of the following traits/risk factors reflect the presence of the syndrome: elevated waist circumference ($102 cm in men, $88 cm in women); reduced HDL-
cholesterol (,1.03 mmol/l in men, ,1.29 mmol/l in women, and/or specific drug treatment); elevated triglycerides ($1.7 mmol/l and/or specific drug treatment);
elevated blood pressure (systolic/diastolic $130/85 mm Hg and/or anti-hypertensive treatment); and elevated fasting plasma glucose ($5.6 mmol/l and/or glucose-
lowering treatment); CRP, C-reactive protein; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule 1; sVCAM-1, soluble vascular cell adhesion
molecule 1.
doi:10.1371/journal.pone.0058576.t001
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SAA, sICAM-1 and sVCAM-1) simultaneously in EDTA plasma.
This system uses multi-array plates fitted with multi-electrodes per
well with each electrode being coated with a different capture
antibody. For the present study the 4-plex assay (plates fitted with
four electrodes per well, i.e. four separate well spots with a
different capture antibody bound to each) was used. The assay
procedure follows that of a classic sandwich ELISA with any of the
analytes of interest captured on the relevant electrode. These
captured analytes were, in turn, detected by a secondary, analyte-
specific, ruthenium-conjugated antibody, which is capable of
emitting light after electrochemical stimulation. This method
minimizes nonspecific signals as the stimulation mechanism
(electricity) is decoupled from the signal (light). According to the
MSD protocol, each sample was analyzed in duplicate on the same
Figure 1. Left panel: comparison of biomarker concentrations between the single-biomarker techniques and the multi-array
platform by weighted Deming regression; Right panel: Bland-Altman plots of the differences between the two methods. (A) CRP, C-
reactive protein (n = 566); (B) SAA, serum amyloid A (n = 563); (C) sICAM-1, soluble intercellular adhesion molecule 1 (n = 566); and (D) sVCAM-1,
soluble vascular cell adhesion molecule 1 (n = 567). For loge transformed data limits of agreement can be converted to original units by anti-log
calculation (e.g., for CRP, e20.25 and e0.26 which are equivalent to 0.78 and 1.30 times or 22% below or 30% above the long axis of CRP, respectively).
doi:10.1371/journal.pone.0058576.g001
Figure 2. Box-and-whisker plots showing median and interquartile (box) and 10th and 90th centiles (whiskers) for each biomarker,
before and after realignment to current (multi-array) concentrations. (A) CRP, C-reactive protein (n = 566); (B) SAA, serum amyloid A
(n = 563); (C) sICAM-1, soluble intercellular adhesion molecule 1 (n = 566); and (D) sVCAM-1, soluble vascular cell adhesion molecule 1 (n = 567); ITB,
immunoturbidimetry; MA, multi-array.
doi:10.1371/journal.pone.0058576.g002
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array plate. All multi-array plates were analyzed within 16 days.
The intra- and inter-assay CVs for the platform of MSD were, for
CRP, 3.0% and 4.1%; for SAA, 2.5% and 11.8%; for sICAM-1,
2.5% and 4.7%; and, for sVCAM-1, 2.6% and 5.0%, respectively.
Variation between production lots of multi-array plates could
influence biomarker measurements. We have evaluated the
possible effect of lot-to-lot variation in the current 4-plex assay
using additional data of previous studies [35,36]. Based on
biomarker data of 6 separate production lots (with an average of
30 plates per lot) the lot-to-lot CV for CRP was 9.8%, for SAA was
28.9%, for sICAM-1 was 3.4% and for sVCAM-1 was 4.9%.
Thus, these variations were quite acceptable, except for SAA. Still,
to avoid any noise due to lot-to-lot variation, all plasma samples of
the CODAM study were measured within a single production lot
of multi-array plates.
Statistical Analyses
Method comparisons. Absolute concentrations of each
biomarker as measured by the single-biomarker techniques and
the multi-array platform were examined on all paired samples
from the CODAM study baseline examination (n= 566 for CRP,
n= 563 for SAA, n= 566 for sICAM-1 and n= 567 for sVCAM-1,
after exclusion of erroneous outliers [37]). Pearson’s correlation
coefficients were used to assess whether the ranking of each
biomarker was similar between methods. Weighted Deming
regression was used to assess the extent of constant and/or
proportional bias between methods [26,27]. This state-of-the-art
statistical technique for method comparison is superior to simple
linear regression by taking into account the error in both the
dependent and independent variables [37,38]. In addition, it
allows random errors of each method to be proportional to the
measured concentrations, such that the ratio of the CVs between
methods remains constant over the concentration ranges (set at 1:1
for regression calculations; e.g. 2% vs. 2% at low ranges, and 10%
vs. 10% at high ranges) [37,38].
Realignment and agreement. We anticipated that absolute
biomarker concentrations, as obtained by either single- or multi-
array methods, would differ due to a lack of standardization.
Realignment of the data would, therefore, be necessary to enable
direct comparison of absolute concentrations. For that purpose we
used equations derived from Deming regression analyses to realign
the data as obtained by one to the other method.
To examine the levels of agreement and verify the absence of
systematic error after the re-alignment procedure, Bland-Altman
plots of the differences between single-biomarker and multi-array
data vs. their mean were obtained [39]. Bland-Altman plots were
drawn on loge transformed data whenever the distribution of the
differences was skewed [39,40]. In addition, two-way mixed effects
models (absolute agreement) were used to calculate intra-class
correlation coefficients (ICC), which reflect similarity in individ-
uals’ rank and similarity in absolute biomarker concentrations as
obtained by single-biomarker techniques (realigned) and multi-array
platform [41]. Note that the results of these analyses are shown in
detail for single-biomarker data realigned to multi-array data for
the following reason. The multi-array platform has recently been
introduced in the CODAM study population and represents the
methodology intended to carry on in follow-up assessments in this
cohort.
Method performance across different cardiovascular risk
groups. We used ANOVA to investigate the extent to which
biomarker concentrations, either assessed by the single-biomarker
techniques or the multi-array platform, increased across categories
of glucose metabolism (i.e. NGM, IGM and DM2), weight (i.e.
normal weight, overweight and obesity), number of traits of the
metabolic syndrome (0–1 RFs, 2 RFs and $3 RFs) and smoking
status (never, ex- and current-smoker), by appreciation of the
group effects. ANOVA for repeated measures were subsequently
used to ascertain whether such patterns of associations were
similar between methods, by appreciation of group-by-method
effects (the P-values of which should then be $0.05). In these
analyses, (non-aligned) individual biomarker data, which are
expressed in different scale units, were first standardized to
comparable units by calculation of Z-scores as follows: (the
individuals’ value – the population mean) \ the population SD.
Per definition, each Z-score has a mean of 0, a SD of 1, and the
same distribution as the absolute biomarker concentration (i.e. the
ranking of individuals in the population remains the same). This
thus enabled a direct comparison of the magnitude of relative
Table 2. Weighted Deming regression.
Regression equations (weighted Deming)a
Variable N pairs Y X intercept slope Sylx
a 95% CI b 95% CI
CRP (mg/l) 566 CRPMA CRPITB 20.33 20.35; 20.31 0.93 0.91; 0.94 0.102
SAA (mg/l) 563 SAAMA SAAELISA 0.47 0.05; 0.90 0.14 0.07; 0.20 0.239
sICAM-1 (mg/l) 566 sICAM-1MA sICAM-1ELISA 36.01 24.63; 47.39 0.53 0.49; 0.56 0.104
sVCAM-1 (mg/l) 567 sVCAM-1MA sVCAM-1ELISA 77.83 58.90; 96.75 0.55 0.51; 0.59 0.124
CRP (mg/l) 566 CRPITB CRPMA 0.35 0.34; 0.37 1.08 1.06; 1.10 0.110
SAA (mg/l) 563 SAAELISA SAAMA 23.46 27.37; 0.45 7.33 4.40; 10.25 1.751
sICAM-1 (mg/l) 566 sICAM-1ELISA sICAM-1MA 268.49 294.71; 242.27 1.90 1.77; 2.03 0.197
sVCAM-1 (mg/l) 567 sVCAM-1ELISA sVCAM-1MA 2141.52 2186.54; 296.49 1.82 1.68; 1.96 0.225
aData are intercepts (a) and (slopes) b of the Deming regression equation, which all differed significantly from 0 and 1, respectively, as indicated by their 95% CI;
rejection of the hypothesis that a= 0 means that the two methods differ at least by a constant amount; rejection of the hypothesis that b= 1 implies that there is a
proportional difference between methods; Sylx are standard deviations of the residuals;
Upper panel: these equations are used as cross-validation equations to realign single-biomarker data (ITB, immunoturbidimetry; or ELISA) to multi-array (MA) data.
Lower panel: these equations are used as cross-validation equations to realign multi-array (MA) data to single-biomarker data (ITB, immunoturbidimetry; or ELISA).
CRP, C-reactive protein; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule 1; sVCAM-1, soluble vascular cell adhesion molecule 1.
doi:10.1371/journal.pone.0058576.t002
Cross-Validation of Multi-Array Technology
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differences in each biomarker by RF categories. All comparisons
included adjustments for sex, age, eGFR and prior CVD and were
conducted among individuals with complete paired data on all
four biomarkers (n = 550).
All analyses were performed with the use of the Statistical
Package for Social Sciences (SPSS Inc, version 15.0, Chicago,
Illinois, USA, www.spss.com), except weighted Deming regression,
which was analyzed using the Analyse-It software (Analyse-it
Software Ltd, Leeds, UK, www.analyse-it.com) for Microsoft
Excel (Microsoft Corporation, Washington, USA, www.microsoft.
com). Statistical significance was set at a P-value ,0.05.
Results
Biomarker Concentrations
Table 1 shows the absolute concentrations of CRP, SAA,
sICAM-1, and sVCAM-1, as measured with the single-biomarker
techniques or the multi-array platform, in the whole study
population and across RFs categories.
Method comparison. Despite the very high Pearson’s
correlation coefficients (i.e. 0.994 for CRP, 0.758 for SAA, 0.816
for sICAM-1 and 0.755 for sVCAM-1) absolute concentrations of
biomarkers as obtained by single-biomarker vs. multi-array
techniques differed considerably. Indeed, weighted Deming
regression analyses for all biomarkers showed significant constant
(intercepts) and proportional (slopes) bias between methods such
that the absolute mean concentrations of all four biomarkers were
lower when measured with the multi-array platform than with the
single-biomarker techniques (Fig. 1A–D, left panels). The above
indicates that, when comparing absolute values, realignment of the
single-biomarker data to the multi-array data (or vice-versa) is thus
warranted.
Realignment and agreement. Realignment of the data as
obtained by different methods was therefore conducted with the
use of the coefficients retrieved from the Deming regression
models (Table 2). Bland-Altman plots of the single-biomarker data
realigned to the multi-array data (Fig. 1A–D, right panels) showed
that no obvious relation of differences between methods with their
mean was present. For all biomarkers, except SAA, Bland-Altman
plots confirmed the removal of systematic bias after the
realignment (all mean values for differences between methods
around 0 (Fig. 1A, 1C and 1D, right panels)). For SAA, a
systematic difference between ELISA and multi-array data still
persisted after the realignment (about 15%, i.e. e0.145 as compared
to their mean (Fig. 1B, right panel)). In addition, the equations
applied for the realignment (Table 2) resulted in similar distributions
of single-biomarker and multi-array data (Fig. 2). The resulting
ICCs between single-biomarker (realigned) and multi-array data
were 0.996 for CRP, 0.711 for SAA, 0.895 for sICAM-1 and 0.858
for sVCAM-1.
Method performance across different cardiovascular risk
groups. Concentrations of all biomarkers, as measured by
single-biomarker or multi-array methods (expressed as Z-scores),
increased significantly across categories of glucose metabolism,
weight, metabolic syndrome and smoking status (all P-trends
#0.028, except for sVCAM-1 and smoking status), independently
of sex, age, eGFR and prior CVD (Table 3). Importantly, the
patterns of associations between RFs level and individual
biomarker concentrations did not differ by method of detection
[all P-values for group*method interaction were .0.05, except for
metabolic syndrome status and LogeCRP (P-value = 0.002)]
(Table 3).
These results did not materially change, when the analyses were
repeated excluding individuals with CRP values .10 mg/l, likely
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to indicate an acute inflammatory response [9,17,18] (data not
shown).
Additional Analyses
A key step in biochemical tests comparison is to ascertain
whether the level of agreement between methods is acceptable
from a clinical standpoint [40]. For CRP, values ,1, 1–3, and
.3 mg/l have been proposed to identify individuals at low,
intermediate and high-risk for incident CVD, respectively,
whereas such values are lacking for the other biomarkers
examined herein. This impairs the appreciation of the clinical
relevance of the limits of agreement between methods obtained for
these biomarkers (Fig. 1B–D, right panels) [8,9]. Still, for CRP we
could ascertain that, on the basis of immunoturbidimetry, 12.9%
of the CODAM Study population would be classified at ‘low risk’,
46.4% at ‘intermediate risk’ and 40.7% at ‘high-risk’; on the basis
of the multi-array platform these numbers would be 28.0%, 39.5%
and 32.5%, respectively (Cohen’s k=0.641, which is a measure of
agreement for categorical data; overall concordance rate of
76.7%). After realignment of the immunoturbidimetry to the
multi-array data and vice versa, the agreement between methods
increased considerably (Cohen’s k of 0.931 and 0.946 and
concordance rates of 95.4 and 96.7%, respectively - Table 4).
Discussion
The present study has three main findings. First, the absolute
concentrations of CRP, SAA, sICAM-1 and sVCAM-1 differed
significantly between the single-biomarker techniques and the
multi-array platform of MSD. Second, equations retrieved by
weighted Deming regression enabled proper realignment of the
data to overcome these absolute differences. Finally, the overall
pattern of associations between levels of the individual biomarkers
with glucose metabolism, weight, metabolic syndrome and
smoking status did not differ by method of detection. This is the
first study that has examined and cross-validated, in a large
ongoing cohort study, measurements of biomarkers of low-grade
inflammation by means of single-biomarker techniques and the
multi-array platform of MSD.
Our results are in line with a previous study, which suggested
that data measured with single-biomarker techniques and data
measured with the multi-array platform cannot be combined
without appropriate realignment of the data as this would distort
epidemiological associations [23]. In our study, the absolute
concentrations of all four biomarkers were lower when measured
with the multi-array platform than with the single-biomarker
techniques. It should be emphasized, however, that the absolute
concentration of each biomarker is based on the standards
provided by the commercial kits and the lack of international
standardization among these may therefore explain the differences
between methods [9]. Although CRP reference materials exist,
bias attributed to standardization remains due to the fact that
reference materials were developed to distinguish between CRP
values below 10 mg/l, from 10 to 40 mg/l and above 40 mg/l,
whereas current assays aim for accurate and reproducible
detection down to 0.3 mg/l [18]. Also according to the Centers
for Disease Control and Prevention and the American Heart
Association laboratory science discussion group, further standard-
ization efforts are therefore required as measurements of absolute
biomarker concentrations are of paramount importance for direct
comparison between studies using different methods and for
definition of clinical cutoff values [18]. Nevertheless, in the present
study we were able to appropriately realign the data to overcome
the absolute differences between both methods. Thus, the
introduction of a multi-array platform in an ongoing cohort study
may be implemented without impairing the investigation of
within-subject changes in biomarker concentrations over the
course of time. This was enabled by re-assaying all the baseline
samples with the new multi-array method. In addition, we show
that the agreement in risk level assignment on the basis of CRP
levels (,1, 1–3, and .3 mg/l [8,9]) is very high after realignment.
It remains, however, that subjects’ risk-level assignment depends
on the method used for CRP assessment, and that if this were done
on the basis of MSD readings, less individuals from the CODAM
Study would be considered to be at high-risk than if this were done
on the basis of immunoturbidimetry readings. However, to
establish which method is superior in risk prediction further
studies are warranted.
Another option to directly compare individual biomarker levels
between methods (but also between clinical studies) is by
transformation of data to Z-scores, especially if realignment
equations are lacking. By Z-score transformation, between-
subjects ranking in terms of their biomarkers levels are preserved
within the population. The present study shows that Z-scores of
CRP, SAA, sICAM-1, sVCAM-1 differed across categories of
glucose metabolism, weight, metabolic syndrome and smoking
status in a similar fashion irrespective of the method of detection.
Although it is evident that a high correlation between assays will
result in identical associations, these results, illustrate and
emphasize that, despite absolute differences, the relative differ-
ences are comparable between the single-biomarker techniques
and the multi-array platform.
Taken together, our findings suggest that the multi-array
platform of MSD could potentially replace the single-biomarker
techniques for the detection of multiple biomarkers in large
ongoing and future clinical studies aiming at the investigation of
the role of low-grade inflammation in the etiology of CVD, though
careful validation would be required.
Furthermore, the multi-array platform of MSD has several
practical advantages over the well-established single-biomarker
techniques for biomarker detection, although CRP assays are
generally automated [18]: 1) it has simple operating procedures; 2)
it has a higher sensitivity and greater detection range, which
eliminates multiple dilutions and freeze and thaw cycles per
sample; 3) it allows determination of four (or more) biomarkers
simultaneously, improving the labor-efficiency, and due costs; and
4) it uses a small sample volume (5 mL instead of 50 mL for the
detection of these four markers), which is useful in clinical and
epidemiological studies.
The present study has some limitations. First, with the single-
biomarker techniques, CRP was measured in serum and SAA,
sVCAM-1 and sICAM-1 were measured in plasma, whereas with
the multi-array platform all biomarkers were measured in plasma.
This may, in part, explain the differences between methods in
absolute concentrations of CRP, since a different matrix might
effect detection. Furthermore, the measurement of biomarkers by
the single-biomarker techniques and the multi-array platform were
performed ,7 years apart, which could also have contributed to
an underestimation of absolute biomarker concentrations by the
multi-array platform. However, because storage time of samples
was the same for all study individuals, if anything: 1) this
underestimation was likely systematic and properly incorporated
in the realignment equations; and 2) could not have affected the
relative differences in biomarkers across different levels of subjects’
cardiovascular RFs. Second, we showed realignment equations to
enable transition of ‘old’ to ‘new’ methods within our ongoing
cohort study (and vice versa). However, the results were shown in
detail for single-biomarker data realigned to multi-array data. This
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way of presentation facilitates future comparisons of those
biomarkers measured with the multi-array platform at follow-up
examinations within this ongoing cohort study. However, any
other cohort study should calculate realignment equations within
their own data. These may be susceptible to lot-to-lot variation,
although in our laboratory the lot-to-lot variation between multi-
array assays was low for most of the biomarkers. Nevertheless, the
measured concentrations will always depend on the standards
provided by the commercial kits (for both the single biomarker and
multi-array techniques), which have not been satisfactorily
standardized internationally [9,18].
In conclusion, multiple biomarker detection by the 4-plex multi-
array platform of MSD including CRP, SAA, sICAM-1 and
sVCAM-1 shows comparable results with well-established single-
biomarker techniques, despite differences in absolute concentra-
tions. Subjects’ risk-level assignment therefore depends on the
method used. It is, however, uncertain which method is superior in
risk prediction. Nevertheless, these biomarkers of low-grade
inflammation are associated with glucose metabolism, weight,
metabolic syndrome and smoking status, irrespective of the
method of detection. In terms of time, effort and quality, this
multi-array platform of MSD is an attractive alternative for single-
biomarker measurements. Therefore, this platform is a potential
tool for the quantification of multiple biomarkers of low-grade
inflammation using small sample volume in one single run in large
ongoing and future clinical studies.
Author Contributions
Critically revised the manuscript: MPHvdW MMJvG CJHvdK RMAH
EJMF CDAS. Read and approved the manuscript: BCTvB IF MPHvdW
MMJvG CJHvdK RMAH EJMF CDAS CGS. Conceived and designed
the experiments: IF MMJvG CJHvdK RMAH EJMF CDAS CGS.
Performed the experiments: BCTvB IF MPHvdW. Analyzed the data:
BCTvB IF MPHvdW. Contributed reagents/materials/analysis tools: IF
MMJvG CJHvdK RMAH EJMF CDAS CGS. Wrote the paper: BCTvB
IF CGS.
References
1. Borissoff JI, Spronk HM, ten Cate H (2011) The hemostatic system as a
modulator of atherosclerosis. N Engl J Med 364: 1746–1760.
2. Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340:
115–126.
3. Becker A, van Hinsbergh VW, Jager A, Kostense PJ, Dekker JM, et al. (2002)
Why is soluble intercellular adhesion molecule-1 related to cardiovascular
mortality? Eur J Clin Invest 32: 1–8.
4. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, et al. (2001)
Circulating cell adhesion molecules and death in patients with coronary artery
disease. Circulation 104: 1336–1342.
5. Kaplan RC, McGinn AP, Baird AE, Hendrix SL, Kooperberg C, et al. (2008)
Inflammation and hemostasis biomarkers for predicting stroke in postmeno-
pausal women: the Women’s Health Initiative Observational Study. J Stroke
Cerebrovasc Dis 17: 344–355.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and
other markers of inflammation in the prediction of cardiovascular disease in
women. N Engl J Med 342: 836–843.
7. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, et al. (2007) Relative
value of inflammatory, hemostatic, and rheological factors for incident
myocardial infarction and stroke: the Edinburgh Artery Study. Circulation
115: 2119–2127.
8. Vasan RS (2006) Biomarkers of cardiovascular disease: molecular basis and
practical considerations. Circulation 113: 2335–2362.
9. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, et al.
(2003) Markers of inflammation and cardiovascular disease: application to
clinical and public health practice: A statement for healthcare professionals from
the Centers for Disease Control and Prevention and the American Heart
Association. Circulation 107: 499–511.
10. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, et al. (2009)
Relation of multiple inflammatory biomarkers to incident atrial fibrillation.
Am J Cardiol 104: 92–96.
11. Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, et al. (2010) A
multimarker approach to assess the influence of inflammation on the incidence
of atrial fibrillation in women. Eur Heart J 31: 1730–1736.
12. Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, et al. (2010)
Multimarker prediction of coronary heart disease risk: the Women’s Health
Initiative. J Am Coll Cardiol 55: 2080–2091.
13. Daniels LB, Maisel AS (2010) Multiple marker approach to risk stratification in
patients with stable coronary artery disease: to have or have not. Eur Heart J 31:
2980–2983.
14. Wang TJ (2010) Multiple biomarkers for predicting cardiovascular events:
lessons learned. J Am Coll Cardiol 55: 2092–2095.
15. Gruson D, Bodovitz S (2010) Rapid emergence of multimarker strategies in
laboratory medicine. Biomarkers 15: 289–296.
16. Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and
regulatory pathways. Physiol Rev 86: 515–581.
17. Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, et al. (2010)
A large multi-centre European study validates high-sensitivity C-reactive protein
(hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
Diabetologia 54: 2801–2810.
18. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, et al. (2004) CDC/
AHA Workshop on Markers of Inflammation and Cardiovascular Disease:
Application to Clinical and Public Health Practice: report from the laboratory
science discussion group. Circulation 110: e545–549.
19. Marchese RD, Puchalski D, Miller P, Antonello J, Hammond O, et al. (2009)
Optimization and validation of a multiplex, electrochemiluminescence-based
detection assay for the quantitation of immunoglobulin G serotype-specific
antipneumococcal antibodies in human serum. Clin Vaccine Immunol 16: 387–
396.
20. Oh ES, Mielke MM, Rosenberg PB, Jain A, Fedarko NS, et al. (2010)
Comparison of conventional ELISA with electrochemiluminescence technology
for detection of amyloid-beta in plasma. J Alzheimers Dis 21: 769–773.
21. Prabhakar U, Eirikis E, Davis HM (2002) Simultaneous quantification of
proinflammatory cytokines in human plasma using the LabMAP assay.
J Immunol Methods 260: 207–218.
22. Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL (2005) Validation
and comparison of luminex multiplex cytokine analysis kits with ELISA:
determinations of a panel of nine cytokines in clinical sample culture
supernatants. J Reprod Immunol 66: 175–191.
23. de Koning L, Liptak C, Shkreta A, Bradwin G, Hu FB, et al. (2012) A multiplex
immunoassay gives different results than singleplex immunoassays which may
bias epidemiologic associations. Clin Biochem doi:10.1016/j.clinbio-
chem.2012.1004.1006.
24. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, et al. (2005)
Hemoglobin A1c measurements over nearly two decades: sustaining comparable
values throughout the Diabetes Control and Complications Trial and the
Epidemiology of Diabetes Interventions and Complications study. Clin Chem
51: 753–758.
25. Cull CA, Manley SE, Stratton IM, Neil HA, Ross IS, et al. (1997) Approach to
maintaining comparability of biochemical data during long-term clinical trials.
Clin Chem 43: 1913–1918.
26. Maahs DM, Jalal D, McFann K, Rewers M, Snell-Bergeon JK (2011) Systematic
shifts in cystatin C between 2006 and 2010. Clin J Am Soc Nephrol 6: 1952–
1955.
27. Selvin E, Coresh J, Zhu H, Folsom A, Steffes MW (2010) Measurement of
HbA1c from stored whole blood samples in the Atherosclerosis Risk in
Communities study. J Diabetes 2: 118–124.
28. Kruijshoop M, Feskens EJ, Blaak EE, de Bruin TW (2004) Validation of
capillary glucose measurements to detect glucose intolerance or type 2 diabetes
mellitus in the general population. Clin Chim Acta 341: 33–40.
29. Du H, van der AD, van Bakel MM, van der Kallen CJ, Blaak EE, et al. (2008)
Glycemic index and glycemic load in relation to food and nutrient intake and
metabolic risk factors in a Dutch population. Am J Clin Nutr 87: 655–661.
30. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, et
al. (2009) Low-grade inflammation can partly explain the association between
the metabolic syndrome and either coronary artery disease or severity of
peripheral arterial disease: the CODAM study. Eur J Clin Invest 39: 437–444.
31. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, et
al. (2010) The association between the metabolic syndrome and peripheral, but
not coronary, artery disease is partly mediated by endothelial dysfunction: the
CODAM study. Eur J Clin Invest 41: 167–175.
32. Thewissen MM, Damoiseaux JG, Duijvestijn AM, van Greevenbroek MM, van
der Kallen CJ, et al. (2010) Abdominal Fat Mass Is Associated With Adaptive
Immune Activation: The CODAM Study. Obesity (Silver Spring) 19: 1690–
1698.
33. van Greevenbroek MM, Jacobs M, van der Kallen CJ, Blaak EE, Jansen EH, et
al. (2012) Human plasma complement C3 is independently associated with
coronary heart disease, but only in heavy smokers (the CODAM study).
Int J Cardiol 154: 158–162.
34. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, et al. (2007) Expressing the
Modification of Diet in Renal Disease Study equation for estimating glomerular
filtration rate with standardized serum creatinine values. Clin Chem 53: 766–
772.
Cross-Validation of Multi-Array Technology
PLOS ONE | www.plosone.org 10 March 2013 | Volume 8 | Issue 3 | e58576
35. van Bussel BC, Schouten F, Henry RM, Schalkwijk CG, de Boer MR, et al.
(2011) Endothelial dysfunction and low-grade inflammation are associated with
greater arterial stiffness over a 6-year period. Hypertension 58: 588–595.
36. van Bussel BC, Henry RM, Schalkwijk CG, Dekker JM, Nijpels G, et al. (2012)
Low-grade inflammation, but not endothelial dysfunction, is associated with
greater carotid stiffness in the elderly: the Hoorn Study. J Hypertens 30: 744–
752.
37. Linnet K (1998) Performance of Deming regression analysis in case of
misspecified analytical error ratio in method comparison studies. Clin Chem
44: 1024–1031.
38. Martin RF (2000) General deming regression for estimating systematic bias and
its confidence interval in method-comparison studies. Clin Chem 46: 100–104.
39. Bland JM, Altman DG (1986) Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1: 307–310.
40. Twomey PJ (2006) How to use difference plots in quantitative method
comparison studies. Ann Clin Biochem 43: 124–129.
41. de Vet HC, Terwee CB, Knol DL, Bouter LM (2006) When to use agreement
versus reliability measures. J Clin Epidemiol 59: 1033–1039.
Cross-Validation of Multi-Array Technology
PLOS ONE | www.plosone.org 11 March 2013 | Volume 8 | Issue 3 | e58576
